Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole in Neonates and Infants with Late-onset Sepsis
NCT05856227Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Reversible Covalent Inhibitors
- Countries
- 8
01
Overview
A Phase 3 trial of ceftobiprole medocaril in neonatal sepsis, sponsored by Basilea Pharmaceutica. Started Aug 2023; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on NCT05856227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856227.